Efficacy of allergen-blocker mechanical barrier gel on symptoms and quality of life in patients with allergic rhinitis


Kose S. S., Atakul G., ASİLSOY S., KARAMAN Ö., UZUNER N., Anal O.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, cilt.276, sa.3, ss.729-734, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 276 Sayı: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1007/s00405-018-5251-6
  • Dergi Adı: EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.729-734
  • Anahtar Kelimeler: Allergen-blocker mechanical barrier gel, Allergic rhinitis, Quality of life score, Visual analogue scale, Symptom score, Pediatrics, APPLIED CELLULOSE POWDER, DOUBLE-BLIND, SEVERITY, UPDATE, IMPACT, TRIAL, CREAM
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

ProposeAllergic rhinitis (AR) is a very common, chronic and global health problem. In the last two decades, the efficiency of barrier-enforcing measures in AR has been investigated. In this study, we aimed to evaluate the effect of allergen-blocker mechanical barrier gel (MBG) (AlerjiSTOP((R))) treatment on symptoms and quality of life score (QoLS) in patients with seasonal and perennial allergic rhinitis.MethodsA single-center, prospective study was conducted between January 2017 and May 2018. Patients diagnosed with allergic rhinitis with a visual analogue scale (VAS) of 5 or higher (moderate/severe) were enrolled in the study. Patients were evaluated in terms of VAS, nasal symptom score (NSS), ocular symptom score (OSS), total symptom score (TSS) and QoLS at baseline, 1 week and 1 month of MBG treatment.ResultsA total of 83 patients with AR were enrolled in the study. Clinical and laboratory examinations showed that 50 (60.2%) patients were mono-sensitized. Allergen-blocker mechanical barrier gel treatment was performed as monotherapy in 22 (26.5%) patients. Median VAS, NSS, OSS and TSS decreased from 7 to 4, 8 to 3, 4 to 0 and 12 to 4, respectively (p<0.0001). Correlation analysis revealed positive correlations between lower pediatric rhinoconjunctivitis quality of life questionnaire scores for patients under 12years of age and decrease in VAS, NSS and TSS (r=0.380, p=0.008; r=0.544, p<0.0001; r=0.543, p<0.0001). Positive correlations were detected between lower rhinoconjunctivitis quality of life questionnaire (self-administered) scores for patients12years of age and decrease in VAS, NSS, OSS and TSS (r=0.703, p<0.0001; r=0.465, p=0.005; r=0.526, p=0.001; r=0.624, p<0.0001).ConclusionIn conclusion, we found significant decrease in all symptom scores and improvement in QoLS of patients treated with MBG as monotherapy and combination therapy.